Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Interchange of vaccine products, SARS-CoV-2 test
Clinical narrative: No adverse events other than testing positive for COVID-19; Interchange of vaccine products; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (No adverse events other than testing positive for COVID-19) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in a 50-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Drug use for unknown indication: Pfizer / BioNTech (Left arm) on 13-Feb-2021. Past adverse reactions to the above products included No adverse event with Pfizer / BioNTech. Concurrent medical conditions included HIV positive, High cholesterol, Grass allergy, Allergy to plants (Trees Allergy), Allergic to dogs and Allergic to cats. Concomitant products included VALACYCLOVIR [VALACICLOVIR], ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE (TRIUMEQ), ROSUVASTATIN from an unknown date to 19-May-2022 and FLUTICASONE PROPIONATE from an unknown date to 19-May-2022 for an unknown indication.   On 13-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-Mar-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). On an unknown date, the patient experienced COVID-19 (No adverse events other than testing positive for COVID-19). At the time of the report, COVID-19 (No adverse events other than testing positive for COVID-19) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) Positive.         It was also reported that patient took other medications/products within 2 weeks of starting the COVID-19 treatment and previously received a COVID-19 vaccine.  It was reported that patient received unspecified drug treatment for treatment of COVID-19 from 18-May-2022 to 23-May-2022.  device date as 03-Jun-2022.  Company comment: This spontaneous case reported by a patient, concerns a 50-year-old male patient with no relevant medical history reported, who experienced the unexpected non-serious AESI of COVID-19 infection, on an unknown date after receiving a dose of mRNA-1273 vaccine, probably third dose of the vaccination schedule. Latency between vaccination and onset of the event could not be assessed. Previously, he had received 1 dose of Pfizer/BioNTech COVID-19 Vaccine and 1 dose of Moderna COVID-19 Vaccine. It was reported that the patient was treated with a Pfizer product starting on 18-MAY-2022 for COVID-19 treatment for 7 days. Details of the onset date, lab results and symptoms of this initial COVID-19 infection was not reported. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.   This case was linked to MOD-2022-584915 (Patient Link).; Sender's Comments: This spontaneous case reported by a patient, concerns a 50-year-old male patient with no relevant medical history reported, who experienced the unexpected non-serious AESI of COVID-19 infection, on an unknown date after receiving a dose of mRNA-1273 vaccine, probably third dose of the vaccination schedule. Latency between vaccination and onset of the event could not be assessed. Previously, he had received 1 dose of Pfizer/BioNTech COVID-19 Vaccine and 1 dose of Moderna COVID-19 Vaccine. It was reported that the patient was treated with a Pfizer product starting on 18-MAY-2022 for COVID-19 treatment for 7 days. Details of the onset date, lab results and symptoms of this initial COVID-19 infection was not reported. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.